NL-OMON24822尚未招募不适用
Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysispatients
Sint Lucas Andreas ziekenhuis0 个研究点目标入组 114 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 114
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Hemodialysis patients older than 18 years
- •2. Secundary hyperparathyroidism
排除标准
- •1. Severe hypercalcemia
- •2. Severe liver failure
研究者
相似试验
尚未招募
不适用
Research to (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidismNL-OMON24070Het Sint Lucas Andreas ziekenhuis114
进行中（未招募）
不适用
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPSSecondary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020708Term: Hyperparathyroidism secondaryEUCTR2007-006645-41-NLSint Lucas Andreas Hospital
招募中
4 期
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.hyperparathyroidismincreased activity of the parathyroids1003394910029149NL-OMON31628Sint Lucas Andreas Ziekenhuis114
终止
4 期
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysisNCT00664430Abbott13
进行中（未招募）
1 期
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitisChronic PancreatitisNCT05664880Cedars-Sinai Medical Center24